ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.

The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment
IoT can help to reduce the burden of clinical trials on patients
Mastering compliance and copyright in healthcare and MedComms